- Cohance Lifesciences has appointed Yann D’Herve as Chief Executive Officer of its CDMO business, effective 1 August 2025.
- D’Herve joins from Evonik’s Healthcare division, where he oversaw global CDMO operations.
Cohance Lifesciences has announced the appointment of Yann D’Herve as Chief Executive Officer of its contract development and manufacturing organisation (CDMO) business. The appointment takes effect from 1 August 2025.
The company’s CDMO platform provides integrated services to global pharmaceutical clients, spanning small molecule APIs, Antibody Drug Conjugates (ADCs), and nucleic acid chemistry. D’Herve’s arrival is expected to support the continued growth of this innovation-led platform.
D’Herve brings decades of experience across pharmaceuticals, healthcare, and speciality chemicals. He previously served as Senior Vice President and General Manager of Evonik’s Healthcare division, overseeing 2,600 employees across nine manufacturing sites, including the company’s CDMO operations. His earlier roles included Vice President of Sales and Services at Evonik, as well as leadership positions in production and operations.
Vivek Sharma, Executive Chairman of Cohance Lifesciences, stated, “We are delighted to welcome Yann to Cohance. His deep experience in leading multifaceted global pharmaceutical services businesses will be of tremendous benefit in accelerating the growth of our CDMO platform.”
